Biologic Drugs

Jun 27, 2017
By Pharmaceutical Technology Editors
BIO report measures decade-long investment and acquisition trends for emerging biotech companies.
Jun 12, 2017
The landmark decision determined that biosimilar makers can notify manufacturers before receiving FDA approval.
Jun 02, 2017
Pharmaceutical Technology
As cost pressures mount as a result of multiple biologics being developed for the same indication, manufacturers can harness process efficiencies to maintain the value of legacy products.
May 30, 2017
By Pharmaceutical Technology Editors
The company will expand its production facilities in Carlow and Cork to meet increased global demand for its medicines and vaccines produced in Ireland.
May 23, 2017
By Pharmaceutical Technology Editors
CBER is moving forward with the development and approval of regenerative medicine advanced therapies.
May 22, 2017
By Pharmaceutical Technology Editors
Ablynx will receive EUR15 million in milestone payment following Merck’s decision to advance ALX-1141 into clinical development. The nanobody was developed by Ablynx under a 2011 collaboration between both parties.
May 15, 2017
Pharmaceutical Technology
Manufacturing for originator molecules is restricted by regulations, but drug makers can exploit newer technologies for the manufacture of biosimilars.
May 15, 2017
Pharmaceutical Technology
The decision to use disposable bioreactors is now driven by commercial rather than technological considerations.
May 15, 2017
Pharmaceutical Technology
A multi-pronged approach to raw materials testing can help mitigate the risk of future contamination events.
May 15, 2017
Pharmaceutical Technology
Understanding the purpose of the biological indicator can guide the development of an effective sterilization process.
native1_300x100
lorem ipsum